Pre-tax profits at the main manufacturing unit of Chanelle Pharmaceuticals last year increased by 79% to €4.89m.
Last October, RTÉ's Dragons' Den investor, Chanelle McCoy stepped down from the board of the family-owned company.
The figures show that, in Ms McCoy's final full year with the company, revenues increased by 14% from €45m to €51.47m in the 12 months to the end of April.
Numbers employed by the company increased from 281 to 318, as staff costs went up from €13m to €14.78m.
The firm last year paid a dividend of €2.25m and this followed a €2m dividend payout in fiscal 2018.
The company is one of a number of pharma entities owned by the Burke family.
The business was established by Ms McCoy’s father, Michael Burke, and the main activity of Chanelle Pharmaceuticals Manufacturing Ltd is the manufacture and sale of veterinary and medical pharma products worldwide together with associated research and development.
The directors state that the company "will continue to pursue new opportunities to grow its products and customer base, through a combination of organic growth, product delivery and expansion of our manufacturing capabilities in our facilities".
On the outlook for the business, the directors state that "with strong market demand for our product and delivery pipeline, the company continues to look forward to the next full year with confidence".
The profit also takes account of non-cash depreciation costs of €1.75m and research and development costs of €1.99m.
Shareholder funds at the end of April totalled €9.5m; that included accumulated profits of €7.2m.
Directors’ pay last year declined sharply from €256,779 to €87,858.
A breakdown of the company’s revenues show that it generated revenues of €25.7m in Ireland, €20.7m in Europe and €6m in 'rest of world’.
The company last year paid €4.8m to acquire property, plant and equipment and this followed a pay-out of €3.4m under that heading in fiscal 2018.
The business last year recorded net cash of €10m from operating activities.
